B. Metzler seel. Sohn & Co. AG Acquires 4,141 Shares of DexCom, Inc. $DXCM

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in DexCom, Inc. by 29.5%, acquiring 4,141 additional shares, raising their total to 18,189 shares valued at approximately $1.24 million.
• Other hedge funds have also enhanced their holdings in DexCom, including Nuveen LLC with a $554 million investment, showing strong institutional interest with 97.75% of the company's shares owned by institutional investors.
• DexCom reported a quarterly revenue of $1.16 billion, surpassing estimates and showing a 15.2% year-over-year increase, with adjusted earnings per share of $0.48, exceeding analyst forecasts.

B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 29.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,189 shares of the medical device company's stock after purchasing an additional 4,141 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in DexCom were worth $1,242,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Ieq Capital LLC raised its stake in DexCom by 21.7% during the 1st quarter. Ieq Capital LLC now owns 64,181 shares of the medical device company's stock valued at $4,383,000 after purchasing an additional 11,437 shares during the period. Rafferty Asset Management LLC increased its holdings in DexCom by 1.6% in the 1st quarter. Rafferty Asset Management LLC now owns 208,239 shares of the medical device company's stock valued at $14,221,000 after acquiring an additional 3,380 shares during the last quarter. J. Stern & Co. LLP increased its holdings in DexCom by 36.4% in the 1st quarter. J. Stern & Co. LLP now owns 37,676 shares of the medical device company's stock valued at $2,573,000 after acquiring an additional 10,051 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in DexCom by 255.0% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 73,348 shares of the medical device company's stock valued at $5,009,000 after acquiring an additional 52,686 shares during the last quarter. Finally, Thematics Asset Management increased its holdings in DexCom by 22.9% in the 1st quarter. Thematics Asset Management now owns 315,392 shares of the medical device company's stock valued at $21,538,000 after acquiring an additional 58,663 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on DXCM shares. Barclays lifted their price target on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. William Blair raised DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Oppenheimer lifted their price objective on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, July 31st. Argus began coverage on DexCom in a research note on Thursday, August 21st. They issued a "buy" rating and a $100.00 price objective on the stock. Finally, The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares in the company, valued at approximately $9,494,254.11. This represents a 1.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,722 shares of company stock worth $1,306,131. 0.32% of the stock is owned by company insiders.

DexCom Price Performance

Shares of DexCom stock traded up $1.80 during trading hours on Thursday, reaching $80.72. The company's stock had a trading volume of 2,591,602 shares, compared to its average volume of 3,921,886. The stock has a market cap of $31.66 billion, a P/E ratio of 56.10, a P/E/G ratio of 1.58 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The firm has a 50 day moving average price of $81.78 and a 200-day moving average price of $79.27. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company's revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.